Allena Pharmaceuticals (ALNA) IPO Opens at $12, Priced at $14

Allena Pharmaceuticals' (Nasdaq: ALNA) IPO opened at $12 after pricing at $14.

Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, ALLN-177, is a first in class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.

You May Also Be Interested In

• China's Moonshot AI Confidentially Filed For Hong Kong IPO - DJ
• Macquarie Upgrades Broadcom Limited (AVGO) to Outperform
• SunPower raises $26.2M in private placement led by Sand Hill Road VCs